The day at a glance · 3 min read
Mood · Risk-On
+62
Sentiment, −100 to +100
Regeneron liver fat normalization
62%
Pfizer Blackstone funding
$1.5B
Eli Lilly 2026 sales forecast
$92B
Key driverPositive clinical readouts from AbbVie migraine trial and Regeneron liver disease study alongside strategic funding deals
Daily briefHealthcare· Money365.Market AI ·

AbbVie, Regeneron Lead Pipeline Wins; Pfizer Lands $1.5B

QULIPTA beats topiramate in migraine; Regeneron's siRNA shows 62% liver fat normalization; Pfizer secures Blackstone funding for obesity program

Big Pharma & Biotech

Bullish
01ABBV
AbbVie (ABBV) reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention against topiramate. The TEMPLE study found QULIPTA achieved superior tolerability compared with topiramate in adults with migraine. QULIPTA also showed better efficacy than topiramate on key migraine prevention endpoints in the Phase 3 TEMPLE trial.
02REGN▲ +4.73%
Regeneron Pharmaceuticals (REGN) reported first-in-human data for CIDEBsiRNA, a liver-targeted siRNA candidate for MASLD (metabolic dysfunction-associated steatotic liver disease). The early study showed sustained normalization of liver fat and improvement in liver injury markers in treated participants. Results were presented at a major medical meeting and published in a top tier journal, extending Regeneron's RNAi ambitions into liver disease.
03PFE
Pfizer (PFE) and Blackstone Life Sciences announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the funding, Blackstone will receive a share of future revenues from the obesity program.
04LLY
Eli Lilly (LLY) shares traded at $1,437.29 as the company raised its 2026 sales forecast to as much as $92 billion, driven by strong demand for obesity and diabetes therapies. The pharmaceutical group has delivered a total return of 474.0% over the past five years.

MedTech & Devices

Neutral

DexCom YTD return

20.75%

DexCom 1-year TSR

34.54%
01DXCM
DexCom (DXCM) is back in focus after Health Canada cleared its G7 sensor for use with the myLoop system powered by CamAPS FX during pregnancy, creating a tightly defined new clinical use case. Health Canada approved use of the DexCom G7 continuous glucose monitoring system (common stock) within the myLoop automated insulin delivery setup for pregnancy, supported by AiDAPT trial data showing improved time in pregnancy-specific glucose targets without added hypoglycemia risk. This approval gives DexCom another sensor option within the myLoop ecosystem in Canada. The share price is up 20.75% year to date, yet the 90-day share price return is down 10.48% and the 30-day move is down 5.54%, pointing to cooling momentum despite a 34.54% total shareholder return over the past year.

Healthcare M&A & Financing

Neutral

Biomatter Series A funding

$18M

Ginkgo Bioworks net loss reduction

44%
DNA
01
Biomatter, the custom enzyme design company, announced the closing of an oversubscribed $18 million Series A financing led by Astanor, with participation from existing investors UVC Partners, Inventure, and Metaplanet. The AI-powered enzyme design platform serves global industry leaders and plans to use the proceeds to scale operations.
02DNA
Ginkgo Bioworks Holdings (DNA) narrowed its net loss 44% and landed Novo Nordisk as its first autonomous lab customer, even as revenue slipped 6% and cash burn stayed high. The synthetic biology company highlighted progress in cost reduction during its Q3 2026 earnings call.

FDA & Regulation

Neutral
01EXEL
Exelixis (EXEL) is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Peters said at an investor event. Peters described the company as approaching a transformational period with the upcoming FDA decision and pivotal clinical data.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy